The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Models, Economic

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Models, Economic


High impact information on Models, Economic

  • A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients [3].
  • In order to allow for the results of recent research, the economic model included the addition of aspirin and aspirin plus an HMG-CoA reductase inhibitor (statin) to medical management [4].
  • Our most economic model is that the HK022 nutL sequence suppresses pL operon terminators in the absence of a phage-encoded antitermination protein [5].
  • Using the labor supply economic model, combinations of heroin, alfentanil, or nalbuphine with relatively low doses of cocaine were found to increase the number of injections per session ("income") and total responses per session ("labor") [6].
  • Of these 29, the 9 studies that assessed the cost of COX-2 inhibitors were all based on decision economic models, compared with only 7 of the remaining 20 studies, which assessed the cost of nonselective NSAIDs [7].

Biological context of Models, Economic


Associations of Models, Economic with chemical compounds


Gene context of Models, Economic

  • An economic model was developed to compare costs of stand-alone anterior lumbar interbody fusion with recombinant human bone morphogenetic protein 2 on an absorbable collagen sponge versus autogenous iliac crest bone graft in a tapered cylindrical cage or a threaded cortical bone dowel [14].
  • In this study we introduce a Markov type economic model for the hospital which calculates all relevant direct costs and savings of HGF therapy and may support decisions on HGF administration [15].
  • Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference [16]?
  • Using an economic model for gout, the annual direct burden of illness for new cases of acute gout can be estimated at 27,378,494 US dollars in the United States. CONCLUSIONS: Gout is an increasingly prevalent condition worldwide and creates a heavy economic burden [17].
  • This paper develops an economic model of the market for treatment of waiting list conditions, in which complainants choose between private treatment, NHS treatment and no hospital treatment [18].


  1. Cost savings in migraine associated with less chest pain on new triptan therapy. Wang, J.T., Barr, C.E., Torigoe, Y., Wang, E., Rowland, C.R., Goldfarb, S.D. The American journal of managed care. (2002) [Pubmed]
  2. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients. Annemans, L., Warie, H., Nechelput, M., Peraux, B. Acta Gastroenterol. Belg. (2004) [Pubmed]
  3. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Lamotte, M., Annemans, L., Lefever, A., Nechelput, M., Masure, J. Diabetes Care (2002) [Pubmed]
  4. Is medical treatment for angina the most cost-effective option? Cleland, J.G., Walker, A. Eur. Heart J. (1997) [Pubmed]
  5. Structure and function of the nun gene and the immunity region of the lambdoid phage HK022. Oberto, J., Weisberg, R.A., Gottesman, M.E. J. Mol. Biol. (1989) [Pubmed]
  6. Self-Administration of cocaine-opioid combinations by rhesus monkeys: evaluation of the role of mu receptor efficacy using labor supply analysis. Rowlett, J.K., Rodefer, J.S., Spealman, R.D. J. Pharmacol. Exp. Ther. (2005) [Pubmed]
  7. Treatment costs to prevent or treat upper gastrointestinal adverse events associated with NSAIDs. Rahme, E., Barkun, A.N., Adam, V., Bardou, M. Drug safety : an international journal of medical toxicology and drug experience. (2004) [Pubmed]
  8. Economic impact of the use of prostaglandin to induce estrus in dairy cows. Fetrow, J., Blanchard, T. J. Am. Vet. Med. Assoc. (1987) [Pubmed]
  9. Economic value of gemcitabine in non-small cell lung cancer. Copley-Merriman, C., Martin, C., Johnson, N., Sacristan, J.A., Drings, P.A., Bosanquet, N. Semin. Oncol. (1996) [Pubmed]
  10. Use of unopposed estrogen in women with uteri: prevalence, clinical implications, and economic consequence. White, V.E., Bennett, L., Raffin, S., Emmett, K., Coleman, M.J. Menopause (New York, N.Y.) (2000) [Pubmed]
  11. The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer. Kelly, K. Ann. Oncol. (1999) [Pubmed]
  12. Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial. von Scheele, B., Peña, B., Wong, J., Niculescu, L. Rheumatology (Oxford, England) (2003) [Pubmed]
  13. First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary. Whitehouse, P.J., Winblad, B., Shostak, D., Bhattacharjya, A., Brod, M., Brodaty, H., Dor, A., Feldman, H., Forette, F., Gauthier, S., Hay, J., Henke, C., Hill, S., Mastey, V., Neumann, P., O'Brien, B., Pugner, K., Sano, M., Sawada, T., Stone, R., Wimo, A. Alzheimer disease and associated disorders. (1998) [Pubmed]
  14. A cost analysis of bone morphogenetic protein versus autogenous iliac crest bone graft in single-level anterior lumbar fusion. Polly, D.W., Ackerman, S.J., Shaffrey, C.I., Ogilvie, J.W., Wang, J.C., Stralka, S.W., Mafilios, M.S., Heim, S.E., Sandhu, H.S. Orthopedics. (2003) [Pubmed]
  15. An economic model to assess the savings from a clinical application of haematopoietic growth factors. Uyl-de Groot, C.A., Vellenga, E., Rutten, F.F. Eur. J. Cancer (1996) [Pubmed]
  16. Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference? Drummond, M.F., Barbieri, M., Wong, J.B. Medical decision making : an international journal of the Society for Medical Decision Making. (2005) [Pubmed]
  17. A literature review of the epidemiology and treatment of acute gout. Kim, K.Y., Ralph Schumacher, H., Hunsche, E., Wertheimer, A.I., Kong, S.X. Clinical therapeutics. (2003) [Pubmed]
  18. An economic model of the market for hospital treatment for non-urgent conditions. Goddard, J.A., Malek, M., Tavakoli, M. Health economics. (1995) [Pubmed]
WikiGenes - Universities